Systemic Anti Cancer Treatment Protocol

Carboplatin Seminoma

PROTOCOL REF: MPHACASEGC (Version No: 1.1)

This protocol has been temporarily amended to include GCSF during operational changes brought about during COVID-19

Approved for use in:

Seminoma, stage 1

Adjuvant

Dosage:

Drug	Dosage	Route	Frequency
Carboplatin	AUC 7	IV	One dose only

Use the Calvert Formula to Calculate the Carboplatin dose:

Dose = Target AUC x (GFR + 25)

EDTA measured uncorrected GFR

Supportive treatments:

Anti-emetic risk - Moderate

Ondansetron 8mg tablets, 8mg twice daily for 3 days

Dexamethasone tablets, 4mg twice daily for 3 days

Domperidone 10mg oral tablets, up to 3 times a day or as required

Filgrastim 300 or 480mcg (weight dependant) s/c for 7 days so start from day 2

Issue Date: 6 th May 2020 Review Date: May 2023	Page 1 of 3	Protocol reference: MPHACASEG	iC
Author: Helen Flint	Authorised by: Helen Poulter-Clark & Joanne McCaughey		Version No:1.1

Extravasation risk:

Irritant – use warm compression if symptoms warrant

Administration:

Day	Drug	Dosage	Route	Diluent and Rate
1	Ondansetron 30 mins before chemotherapy	16mg	РО	
1	Dexamethasone 30 mins before chemotherapy	8mg	РО	
1	Carboplatin	AUC 7	IV	500mL glucose 5% over 60 minutes

One dose only

Notes:

Use the Calvert Formula to Calculate the Carboplatin dose:

Dose = Target AUC x (GFR + 25)

Measure uncorrected GFR using EDTA

Do NOT use Cockroft and Gault to calculate creatinine clearance

Do **not** "cap" the EDTA result

Main Toxicities:

Myelosuppression, infertility, nausea and vomiting, allergic reactions, alopecia (rare)

Investigations and treatment plan

Pre-treatment investigations:

FBC

U&Es, including LFTs

LDH

AFP

βHCG

Weight

Informed consent

Issue Date: 6 th May 2020 Review Date: May 2023	Page 2 of 3	Protocol reference: MPHACASEG	ic .
Author: Helen Flint	Authorised by: Helen Poulter-Clark & Joanne McCaughey		Version No:1.1

Dose Modifications and Toxicity Management:

Haematological toxicity

Proceed on day of treatment if:

Contact the prescribing team if these parameters are not met.

Non-haematological toxicity

	See also notes above. Always obtain an EDTA measured GFR and use the Calvert formula to calculate the Carboplatin dose Carboplatin is contraindicated if CrCl < 20ml/minute
Hepatic	None

References:

Clin Genitourin Cancer 2015 Apr 20 Petrelli F et al JCO 10 March 2011 Vol 29 (8) p957 Oliver RTD et al

Issue Date: 6 th May 2020 Review Date: May 2023	Page 3 of 3	Protocol reference: MPHACASEG	С
Author: Helen Flint	Authorised by: Helen Poulter-Clark & Joanne McCaughey		Version No:1.1